Clinical management of Duchenne muscular dystrophy: the state of the art

Messina S, Vita GL. Clinical management of Duchenne muscular dystrophy: the state of the art. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2018;39:1837-1845

Messina_2018_Neurol Sci. Nov;39(11);1837-1845

Review discussing the current care for Duchenne patients.

Abstract

INTRODUCTION: Duchenne muscular dystrophy (DMD) is a devastating, progressive neuromuscular disorder for which there is no cure. As the dystrophin gene is located on the X chromosome, DMD occurs predominately in males. DMD is caused by a lack of functional dystrophin protein resulting from mutations in the 2.2-Mb DMD gene, which disrupts the reading frame. Care considerations for DMD advocate a coordinated, multidisciplinary approach to the management of DMD in order to optimize management of the primary manifestations of DMD as well as any secondary complications that may arise.

METHODS: This review provides an overview of the multidisciplinary clinical management of DMD with regard to the respiratory, cardiology, orthopedic, and nutritional needs of patients with DMD. Recent advances in novel disease-modifying treatments for DMD are also discussed with specific reference to exon skipping and suppression of premature stop codons as promising genetic therapies.

RESULTS: The combination of multidisciplinary clinical management alongside novel gene therapies offers physicians a powerful armamentarium for the treatment of DMD.

search previous next tag category expand menu location phone mail time cart zoom edit close